136
Participants
Start Date
May 31, 2016
Primary Completion Date
May 15, 2019
Study Completion Date
June 14, 2019
Text Messaging
All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
Adherence Counseling
All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
Daily Oral PrEP
All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
APLA Health & Wellness' Gleicher / Chen Health Center, Los Angeles
Los Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles
USC 5P21 Rand Schrader Clinic, Los Angeles
T.H.E. at Ruth Temple, Los Angeles
UCSD Antiviral Research Center, San Diego
University of California, San Diego
OTHER
California HIV/AIDS Research Program
OTHER
Los Angeles County Department of Public Health
OTHER_GOV
AIDS Project Los Angeles
OTHER
University of California, Los Angeles
OTHER